# US 2022/0031677 A1 · Amorphous kinase inhibitor formulations and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031677 A1
- Document ID: US20220031677A1
- Status: Published application
- Kind: A1
- Application number: 17/504,133
- Filed: 2021-10-18
- Published: 2022-02-03
- Earliest claimed: 2019-12-30
- Assignees: Deciphera Pharmaceuticals, LLC
- Applicants: Deciphera Pharmaceuticals, LLC
- Inventors: Michael D. Kaufman; Scott Bone; Corey Bloom; Fred Jordan
- Web page: https://patentgrep.com/patent/US20220031677A1

## CPC

- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 35/00: Antineoplastic agents
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1682: {Processes}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 47/38: Cellulose; Derivatives thereof
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.

## Claims

### Claim 1

A pharmaceutically acceptable composition for orally delivering 50 mg of a compound represented by Formula (I):
comprising:
an intragranular blend, wherein the intragranular blend comprises:
(i) a solid dispersion having 50 mg of the compound wherein the compound is present in amorphous form and hydroxypropyl methyl cellulose acetate succinate;
(ii) about 25-35% by weight microcrystalline cellulose based on the total amount of the pharmaceutically acceptable composition;
(iii) about 25-35% by weight of lactose or a hydrate thereof based on the total amount of the pharmaceutically acceptable composition;
(iv) about 5% by weight of crospovidone based on the total amount of the pharmaceutically acceptable composition;
(v) about 0.5% by weight of silicon dioxide based on the total amount of the pharmaceutically acceptable composition; and
(vi) about 0.5% by weight of magnesium stearate based on the total amount of the pharmaceutically acceptable composition; and
an extragranular blend, wherein the extragranular blend comprises
(i) about 0.5% by weight of silicon dioxide based on the total amount of the pharmaceutically acceptable composition; and
(ii) about 0.5% by weight of magnesium stearate based on the total amount of the of the pharmaceutically acceptable composition;
wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 10 minutes to after about 40 minutes when the composition is tested in 900 mL sodium acetate buffer at pH 4.5 using a USP Apparatus II (Paddle Method) at 37° C., with a paddle speed of 75 rpm.

### Claim 2 (depends on 1)

The pharmaceutically acceptable composition of claim 1, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 10 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 3 (depends on 1)

The pharmaceutically acceptable composition of claim 1, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 20 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at 37° C., with a paddle speed of 75 rpm.

### Claim 4 (depends on 1)

The pharmaceutically acceptable composition of claim 1, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 30 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 5 (depends on 1)

The pharmaceutically acceptable composition of claim 1, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 40 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 6 (depends on 1)

The pharmaceutically acceptable composition of claim 1, comprising less than about 3% by weight of an impurity compound represented by Formula (II):
based on the weight of the compound of Formula (I).

### Claim 7 (depends on 1)

The pharmaceutically acceptable composition of claim 1, wherein the compound and the hydroxypropyl methyl cellulose acetate succinate are present in a ratio of compound:hydroxypropyl methyl cellulose acetate succinate of about 25:75.

### Claim 8

A pharmaceutically acceptable composition for orally delivering 50 mg of a compound represented by Formula (I):
comprising:
an intragranular blend, wherein the intragranular blend comprises:
a) a solid dispersion comprising:
i) 50 mg of the compound, wherein the compound is present in amorphous form, and
ii) hydroxypropyl methyl cellulose acetate succinate;
b) microcrystalline cellulose; and
c) lactose or a hydrate thereof,
and
an extragranular blend, wherein the extragranular blend comprises a glidant;
wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 10 minutes to a after bout 40 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 9 (depends on 8)

The pharmaceutically acceptable composition of claim 8, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 10 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 10 (depends on 8)

The pharmaceutically acceptable composition of claim 8, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 20 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 11 (depends on 8)

The pharmaceutically acceptable composition of claim 8, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 30 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 12 (depends on 8)

The pharmaceutically acceptable composition of claim 8, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 40 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 13 (depends on 8)

The pharmaceutically acceptable composition of claim 8, wherein the glidant is silicon dioxide.

### Claim 14 (depends on 8)

The pharmaceutically acceptable composition of claim 8, wherein the extragranular blend comprises:
about 0.5% by weight of silicon dioxide based on the total amount of the pharmaceutically acceptable composition; and
about 0.5% by weight of magnesium stearate based on the total amount of the of the pharmaceutically acceptable composition.

### Claim 15 (depends on 8)

The pharmaceutically acceptable composition of claim 8, comprising less than about 3% by weight of an impurity compound represented by Formula (II):
based on the weight of the compound of Formula (I).

### Claim 16 (depends on 8)

The pharmaceutically acceptable composition of claim 8, wherein the compound and the hydroxypropyl methyl cellulose acetate succinate are present in a ratio of compound:hydroxypropyl methyl cellulose acetate succinate of about 25:75.

### Claim 17

A pharmaceutically acceptable composition for orally delivering 50 mg of a compound represented by Formula (I):
comprising:
an intragranular blend, wherein the intragranular blend comprises:
a) a solid dispersion comprising:
i) 50 mg of the compound, wherein the compound is present in amorphous form, and
ii) hydroxypropyl methyl cellulose acetate succinate; and
an extragranular blend, wherein the extragranular blend comprises a glidant;
wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 10 minutes to after about 40 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 18 (depends on 17)

The pharmaceutically acceptable composition of claim 17, comprising:
b) about 25-35% by weight microcrystalline cellulose based on the total amount of the pharmaceutically acceptable composition.

### Claim 19 (depends on 17)

The pharmaceutically acceptable composition of claim 17, comprising:
c) about 25-35% by weight of lactose or a hydrate thereof based on the total amount of the pharmaceutically acceptable composition.

### Claim 20 (depends on 17)

The pharmaceutically acceptable composition of claim 17, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 10 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 21 (depends on 17)

The pharmaceutically acceptable composition of claim 17, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 20 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 22 (depends on 17)

The pharmaceutically acceptable composition of claim 17, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 30 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 23 (depends on 17)

The pharmaceutically acceptable composition of claim 17, wherein the pharmaceutically acceptable composition releases at least 80% of the compound after about 40 minutes when the composition is tested in 900 mL sodium acetate buffer at pH about 4.5 using a USP Apparatus II (Paddle Method) at about 37° C., with a paddle speed of about 75 rpm.

### Claim 24 (depends on 17)

The pharmaceutically acceptable composition of claim 17, wherein the glidant is silicon dioxide.

### Claim 25 (depends on 17)

The pharmaceutically acceptable composition of claim 17, wherein the extragranular blend comprises:
about 0.5% by weight of silicon dioxide based on the total amount of the pharmaceutically acceptable composition; and
about 0.5% by weight of magnesium stearate based on the total amount of the of the pharmaceutically acceptable composition.

### Claim 26 (depends on 17)

The pharmaceutically acceptable composition of claim 17, comprising less than about 3% by weight of an impurity compound represented by Formula (II):
based on the weight of the compound of Formula (I).

### Claim 27 (depends on 17)

The pharmaceutically acceptable composition of claim 17, wherein the compound and the hydroxypropyl methyl cellulose acetate succinate are present in a ratio of compound:hydroxypropyl methyl cellulose acetate succinate of about 25:75.
